Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …

Background & Aims Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to
off-label use of corticosteroids not optimized for esophageal delivery. We performed a …

Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier
phase 2 induction study, etrolizumab significantly improved clinical remission compared …

Background & Aims Gluten ingestion leads to symptoms and small intestinal mucosal injury
in patients with celiac disease. The only option is the strict lifelong exclusion of dietary gluten…

… Kane) were involved in the design and execution of the study, interpretation of the results,
and drafting and final approval of the manuscript; Raman Patel and Keith Friedenberg were …

Background A gluten-free diet is insufficient to treat coeliac disease because intestinal injury
persists and acute reactions with cytokine release follow gluten exposure. Nexvax2 is a …

Coinciding with the increasing rates of cannabis abuse has been the recognition of a new
clinical condition known as Cannabinoid Hyperemesis Syndrome. Cannabinoid Hyperemesis …

Nearly all epidemiologic studies have found an association between increasing body mass
index (BMI) and symptoms of gastroesophageal reflux disease (GERD). Changes in …

Background & Aims We evaluated treatment withdrawal, long-term outcomes, and safety of
budesonide oral suspension (BOS) 2.0 mg twice daily in patients with eosinophilic …

Background The prevalence and severity of duodenal injury in coeliac disease patients
controlled on a gluten‐free diet is unclear. Aims To use quantitative histology to assess …